Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
暂无分享,去创建一个
Valérie Taly | Pierre Laurent-Puig | P. Laurent-Puig | J. Vaillant | S. Doat | V. Taly | J. Bachet | F. Imbert‐Bismut | O. Dubreuil | Olivier Dubreuil | Audrey Didelot | Jean-Baptiste Bachet | Jean-Christophe Vaillant | Fanny Garlan | Nicolas Pécuchet | A. Didelot | F. Garlan | D. Pietrasz | Mehdi Karoui | Daniel Pietrasz | Solène Doat | Francoise Imbert-Bismut | M. Karoui | N. Pécuchet
[1] P. Laurent-Puig,et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. , 2013, Clinical chemistry.
[2] A. Harris,et al. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR , 2004, British Journal of Cancer.
[3] Niels Pallisgaard,et al. Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan , 2012, Clinical Cancer Research.
[4] C. Logsdon,et al. Roles for KRAS in pancreatic tumor development and progression. , 2013, Gastroenterology.
[5] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[6] Ahmedin Jemal,et al. Annual Report to the Nation on the status of cancer, 1975‐2008, featuring cancers associated with excess weight and lack of sufficient physical activity , 2012, Cancer.
[7] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[8] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[9] B. Tops,et al. Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium , 2015, BMC Cancer.
[10] L. Mazutis,et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. , 2011, Lab on a chip.
[11] Z. Meng,et al. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[12] R. Strausberg,et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[14] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[15] A. Jemal,et al. Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.
[16] Karin Haustermans,et al. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). , 2014, European journal of cancer.
[17] G. Launoy,et al. Incidence of gastrointestinal cancers in France. , 2004, Gastroenterologie clinique et biologique.
[18] I. Brandslund,et al. Cell‐free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer , 2014, International journal of cancer.
[19] K. Nouso,et al. Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer , 2015, Cancer.
[20] L. Castellano,et al. Circulating molecular markers in pancreatic cancer: ready for clinical use? , 2013, Future oncology.
[21] P. Pasqualetti,et al. Low Correspondence Between K-ras Mutations in Pancreatic Cancer Tissue and Detection of K-ras Mutations in Circulating DNA , 2006, Pancreas.
[22] R. Hruban,et al. Progress in cancer genetics: lessons from pancreatic cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] R. DePinho,et al. Pancreatic cancer biology and genetics , 2002, Nature Reviews Cancer.
[24] R. Scharpf,et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients , 2015, Nature Communications.
[25] Jason Y. Park,et al. Molecular signatures of pancreatic cancer. , 2011, Archives of pathology & laboratory medicine.
[26] H. Oettle,et al. Follow-Up Study of K-ras Mutations in the Plasma of Patients With Pancreatic Cancer: Correlation With Clinical Features and Carbohydrate Antigen 19-9 , 2009, Pancreas.
[27] A. Lièvre,et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Y. Rozenholc,et al. Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA. , 2016, Clinical chemistry.
[29] M A Firpo,et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. , 2013, Current molecular medicine.
[30] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[31] U. Pastorino,et al. Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer , 2003 .